{"id":6321,"date":"2024-10-30T18:50:51","date_gmt":"2024-10-30T17:50:51","guid":{"rendered":"https:\/\/ern-ithaca.eu\/?page_id=6321"},"modified":"2025-04-04T14:58:30","modified_gmt":"2025-04-04T12:58:30","slug":"valproate-embryopathy-guideline","status":"publish","type":"page","link":"https:\/\/ern-ithaca.eu\/es\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/","title":{"rendered":"Gu\u00eda sobre la embriopat\u00eda por valproato"},"content":{"rendered":"<p class=\"has-vivid-cyan-blue-color has-text-color has-link-color wp-elements-1 wp-block-paragraph\"><em><strong>Esta recomendaci\u00f3n se ajusta a los \u00faltimos resultados de investigaci\u00f3n disponibles a fecha de octubre de 2018.<\/strong><\/em><\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"background\">Antecedentes<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Se ha descrito un patr\u00f3n de anomal\u00edas cong\u00e9nitas graves y leves, rasgos dism\u00f3rficos faciales y dificultades en el desarrollo neurol\u00f3gico \u2014incluidas las alteraciones cognitivas y sociales\u2014 en algunos ni\u00f1os expuestos al valproato de sodio (VPA) durante el embarazo. El reconocimiento del aumento del riesgo de malformaciones cong\u00e9nitas \u2014y, en particular, de los efectos sobre el desarrollo neurol\u00f3gico\u2014 asociado a la exposici\u00f3n intrauterina al VPA ha llevado muchos a\u00f1os, pero estos riesgos se reconocen ahora tras la publicaci\u00f3n de los resultados de varios estudios prospectivos y registros. Al igual que con otros terat\u00f3genos, la exposici\u00f3n al VPA puede tener efectos variables, que van desde un patr\u00f3n caracter\u00edstico de malformaciones graves y discapacidad intelectual significativa hasta el otro extremo del espectro, caracterizado por una dismorfia facial que a menudo resulta dif\u00edcil de discernir y un efecto m\u00e1s moderado sobre el desarrollo neurol\u00f3gico y la salud general. Ha quedado claro que algunas personas con FVSD tienen necesidades complejas que requieren una atenci\u00f3n multidisciplinar, pero actualmente se carece de informaci\u00f3n sobre su tratamiento en la literatura m\u00e9dica.<\/p>\n\n\n\n<div style=\"height:46px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"methods\">M\u00e9todos<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">ERN-ITHACA, la Red Europea de Referencia para las Malformaciones Cong\u00e9nitas y la Discapacidad Intelectual, convoc\u00f3 a un grupo de expertos compuesto por profesionales dedicados a la atenci\u00f3n de personas con FVSD y con representaci\u00f3n de los pacientes. Se llev\u00f3 a cabo una revisi\u00f3n de la bibliograf\u00eda publicada y no publicada relativa al tratamiento de la FVSD y se clasific\u00f3 el nivel de evidencia de estas fuentes. Se formularon recomendaciones de tratamiento basadas en la solidez de la evidencia y en el consenso de los expertos, en el marco de una reuni\u00f3n de consenso de expertos. Posteriormente, estas recomendaciones se perfeccionaron mediante un proceso iterativo y una consulta m\u00e1s amplia.<\/p>\n\n\n\n<div style=\"height:46px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"results\">Resultados<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Si bien exist\u00edan pruebas s\u00f3lidas sobre el aumento del riesgo de malformaciones cong\u00e9nitas graves y dificultades en el desarrollo neurol\u00f3gico, se echaba en falta evidencia de alto nivel en otros \u00e1mbitos y, en particular, en lo que respecta al tratamiento cl\u00ednico \u00f3ptimo. El enfoque de consenso de expertos facilit\u00f3 la formulaci\u00f3n de recomendaciones de manejo, basadas en la evidencia de la literatura y en las mejores pr\u00e1cticas. El resultado de la revisi\u00f3n y de los debates en grupo nos lleva a proponer el t\u00e9rmino \u00abtrastorno del espectro del valproato fetal\u00bb (FVSD, por sus siglas en ingl\u00e9s), ya que consideramos que este abarca mejor la amplia gama de efectos observados tras la exposici\u00f3n al VPA en el \u00fatero.<\/p>\n\n\n\n<div style=\"height:46px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"conclusion\">Conclusi\u00f3n<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">El enfoque basado en el consenso de expertos puede utilizarse para definir las mejores recomendaciones cl\u00ednicas disponibles para el diagn\u00f3stico y el tratamiento de enfermedades raras como el FVSD. El FVSD puede tener repercusiones m\u00e9dicas, del desarrollo y neuropsicol\u00f3gicas con consecuencias que duran toda la vida, y las personas afectadas se benefician de la colaboraci\u00f3n de diversos profesionales sanitarios.<\/p>\n\n\n\n<div style=\"height:46px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"reference\">Referencia<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Clayton-Smith J, Bromley R, Dean J, Journel H, Odent S, Wood A, Williams J, Cuthbert V, Hackett L, Aslam N, Malm H, James G, Westbom L, Day R, Ladusans E, Jackson A, Bruce I, Walker R, Sidhu S, Dyer C, Ashworth J, Hindley D, D\u00edaz GA, Rawson M, Turnpenny P.&nbsp;<a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6642533\/\">Diagn\u00f3stico y tratamiento de las personas con trastorno del espectro del valproato fetal: declaraci\u00f3n de consenso de la Red Europea de Referencia para las Malformaciones Cong\u00e9nitas y la Discapacidad Intelectual<\/a>. Orphanet J Rare Dis. 19 de julio de 2019; 14(1):180. PMID:31324220<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6642533\/\">Consulta la publicaci\u00f3n completa en PubMed<\/a><\/strong><\/p>","protected":false},"excerpt":{"rendered":"<p>This recommendation is aligned with the latest research findings available as of October 2018. Background A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium&nbsp;valproate&nbsp;(VPA) during pregnancy. Recognition of the increased risks of in utero exposure to [&hellip;]<\/p>\n","protected":false},"author":253,"featured_media":0,"parent":97,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-6321","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valproate embryopathy guideline - ERN ITHACA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ern-ithaca.eu\/es\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valproate embryopathy guideline - ERN ITHACA\" \/>\n<meta property=\"og:description\" content=\"This recommendation is aligned with the latest research findings available as of October 2018. Background A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium&nbsp;valproate&nbsp;(VPA) during pregnancy. Recognition of the increased risks of in utero exposure to [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ern-ithaca.eu\/es\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/\" \/>\n<meta property=\"og:site_name\" content=\"ERN ITHACA\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-04T12:58:30+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ERNIthaca\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/guidelines\\\/ern-ithaca-guidelines\\\/valproate-embryopathy-guideline\\\/\",\"url\":\"https:\\\/\\\/ern-ithaca.eu\\\/guidelines\\\/ern-ithaca-guidelines\\\/valproate-embryopathy-guideline\\\/\",\"name\":\"Valproate embryopathy guideline - ERN ITHACA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/#website\"},\"datePublished\":\"2024-10-30T17:50:51+00:00\",\"dateModified\":\"2025-04-04T12:58:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/guidelines\\\/ern-ithaca-guidelines\\\/valproate-embryopathy-guideline\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ern-ithaca.eu\\\/guidelines\\\/ern-ithaca-guidelines\\\/valproate-embryopathy-guideline\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/guidelines\\\/ern-ithaca-guidelines\\\/valproate-embryopathy-guideline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ern-ithaca.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Guidelines\",\"item\":\"https:\\\/\\\/ern-ithaca.eu\\\/guidelines\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"ERN ITHACA Guidelines\",\"item\":\"https:\\\/\\\/ern-ithaca.eu\\\/guidelines\\\/ern-ithaca-guidelines\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Valproate embryopathy guideline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/#website\",\"url\":\"https:\\\/\\\/ern-ithaca.eu\\\/\",\"name\":\"ERN ITHACA\",\"description\":\"WELCOME TO ERN-ITHACA WEBSITE!\",\"publisher\":{\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ern-ithaca.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/#organization\",\"name\":\"ERN-ITHACA\",\"url\":\"https:\\\/\\\/ern-ithaca.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ern-ithaca.eu\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Logo-ERN-ITHACA.jpg\",\"contentUrl\":\"https:\\\/\\\/ern-ithaca.eu\\\/wp-content\\\/uploads\\\/2022\\\/02\\\/Logo-ERN-ITHACA.jpg\",\"width\":454,\"height\":172,\"caption\":\"ERN-ITHACA\"},\"image\":{\"@id\":\"https:\\\/\\\/ern-ithaca.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ERNIthaca\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ithaca-european-reference-network-on-congenital-malformations-ans-rare-intellectual-disability\\\/?viewAsMember=true\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valproate embryopathy guideline - ERN ITHACA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ern-ithaca.eu\/es\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/","og_locale":"es_ES","og_type":"article","og_title":"Valproate embryopathy guideline - ERN ITHACA","og_description":"This recommendation is aligned with the latest research findings available as of October 2018. Background A pattern of major and minor congenital anomalies, facial dysmorphic features, and neurodevelopmental difficulties, including cognitive and social impairments has been reported in some children exposed to sodium&nbsp;valproate&nbsp;(VPA) during pregnancy. Recognition of the increased risks of in utero exposure to [&hellip;]","og_url":"https:\/\/ern-ithaca.eu\/es\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/","og_site_name":"ERN ITHACA","article_modified_time":"2025-04-04T12:58:30+00:00","twitter_card":"summary_large_image","twitter_site":"@ERNIthaca","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ern-ithaca.eu\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/","url":"https:\/\/ern-ithaca.eu\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/","name":"Valproate embryopathy guideline - ERN ITHACA","isPartOf":{"@id":"https:\/\/ern-ithaca.eu\/#website"},"datePublished":"2024-10-30T17:50:51+00:00","dateModified":"2025-04-04T12:58:30+00:00","breadcrumb":{"@id":"https:\/\/ern-ithaca.eu\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ern-ithaca.eu\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ern-ithaca.eu\/guidelines\/ern-ithaca-guidelines\/valproate-embryopathy-guideline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ern-ithaca.eu\/"},{"@type":"ListItem","position":2,"name":"Guidelines","item":"https:\/\/ern-ithaca.eu\/guidelines\/"},{"@type":"ListItem","position":3,"name":"ERN ITHACA Guidelines","item":"https:\/\/ern-ithaca.eu\/guidelines\/ern-ithaca-guidelines\/"},{"@type":"ListItem","position":4,"name":"Valproate embryopathy guideline"}]},{"@type":"WebSite","@id":"https:\/\/ern-ithaca.eu\/#website","url":"https:\/\/ern-ithaca.eu\/","name":"ERN ITHACA","description":"WELCOME TO ERN-ITHACA WEBSITE!","publisher":{"@id":"https:\/\/ern-ithaca.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ern-ithaca.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ern-ithaca.eu\/#organization","name":"ERN-ITHACA","url":"https:\/\/ern-ithaca.eu\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ern-ithaca.eu\/#\/schema\/logo\/image\/","url":"https:\/\/ern-ithaca.eu\/wp-content\/uploads\/2022\/02\/Logo-ERN-ITHACA.jpg","contentUrl":"https:\/\/ern-ithaca.eu\/wp-content\/uploads\/2022\/02\/Logo-ERN-ITHACA.jpg","width":454,"height":172,"caption":"ERN-ITHACA"},"image":{"@id":"https:\/\/ern-ithaca.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ERNIthaca","https:\/\/www.linkedin.com\/company\/ithaca-european-reference-network-on-congenital-malformations-ans-rare-intellectual-disability\/?viewAsMember=true"]}]}},"_links":{"self":[{"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/pages\/6321","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/users\/253"}],"replies":[{"embeddable":true,"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/comments?post=6321"}],"version-history":[{"count":2,"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/pages\/6321\/revisions"}],"predecessor-version":[{"id":7380,"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/pages\/6321\/revisions\/7380"}],"up":[{"embeddable":true,"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/pages\/97"}],"wp:attachment":[{"href":"https:\/\/ern-ithaca.eu\/es\/wp-json\/wp\/v2\/media?parent=6321"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}